Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have received an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $33.1667.

IMNM has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Barclays assumed coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Craig Hallum boosted their price target on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Stephens reduced their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Finally, Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Immunome Trading Down 1.3%

IMNM stock opened at $18.16 on Thursday. The firm’s 50-day moving average price is $21.92 and its two-hundred day moving average price is $21.71. Immunome has a 12-month low of $7.96 and a 12-month high of $27.65. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -7.63 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities analysts predict that Immunome will post -2.06 EPS for the current year.

Insider Activity at Immunome

In related news, Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Max Rosett sold 65,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. This represents a 54.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,438 shares of company stock worth $2,964,664 over the last ninety days. Corporate insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

Hedge funds and other institutional investors have recently bought and sold shares of the business. NEOS Investment Management LLC grew its holdings in Immunome by 40.5% in the third quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock worth $1,899,000 after purchasing an additional 46,755 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in Immunome in the third quarter worth about $5,884,000. TD Asset Management Inc grew its holdings in Immunome by 15.8% in the third quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock worth $8,212,000 after purchasing an additional 95,750 shares during the period. Principal Financial Group Inc. grew its holdings in Immunome by 222.3% in the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after purchasing an additional 762,147 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Immunome by 1,749.3% in the fourth quarter. SG Americas Securities LLC now owns 162,168 shares of the company’s stock worth $3,483,000 after purchasing an additional 153,399 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.